Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study

S R Meikle, J C Matthews, C S Brock, P Wells, R J Harte, V J Cunningham, T Jones, P Price

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The aim of this study was to investigate the feasibility of evaluating the pharmacokinetics of radiolabeled anti-cancer drugs using spectral analysis, a non-compartmental tracer kinetic modeling technique, and positron emission tomography (PET).
Original languageEnglish
Pages (from-to)183-93
Number of pages11
JournalCancer Chemotherapy and Pharmacology
Volume42
Issue number3
Publication statusPublished - 1998

Keywords

  • Acridines
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents, Alkylating
  • Colorectal Neoplasms
  • Dacarbazine
  • Feasibility Studies
  • Female
  • Fluorouracil
  • Glioma
  • Humans
  • Middle Aged
  • Spectrum Analysis
  • Tomography, Emission-Computed

Fingerprint Dive into the research topics of 'Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study'. Together they form a unique fingerprint.

  • Cite this

    Meikle, S. R., Matthews, J. C., Brock, C. S., Wells, P., Harte, R. J., Cunningham, V. J., Jones, T., & Price, P. (1998). Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemotherapy and Pharmacology, 42(3), 183-93.